How Stem Cells Are Rewriting the Cure for Type 1 Diabetes

Type 1 diabetes develops when the body’s immune system mistakenly attacks its own beta cells – the cells in the pancreas that produce insulin. This means that any cure requires scientists to solve two problems. First, finding a reliable source of healthy beta cells so that they can be transplanted into an affected person. Second, preventing the individual’s immune system from attacking the transplanted beta cells in the same way that it attacked the person’s own beta cells.

Healthy people cannot donate some of their own beta cells in their pancreas, and it is difficult to harvest enough beta cells from deceased donors. Scientists are therefore turning to human stem cells as a solution. These are “blank slate” cells that can theoretically be multiplied indefinitely in a lab, offering a limitless supply of replacement beta cells. To create these replacements, scientists use a biological process that mimics nature. The addition of a carefully timed “recipe” of chemical signals to the stem cells over several weeks guides these cells through the same stages that a baby’s pancreas goes through before birth. Although still in research, there is a lot of promise to this approach, and there are already clinical trials in humans. So far, early findings have shown that cells can survive, produce insulin, and even allow some patients to completely stop taking daily insulin shots.

However, replacing the beta cells is only half the battle. Preventing the immune system from attacking the new cells is an equally challenging problem. Currently, transplant patients must take strong, lifelong drugs to suppress their immune system to prevent rejection. To avoid this, scientists are designing physical capsules to encapsulate and protect cells. They are also using gene-editing tools like CRISPR to build a biological “invisibility cloak”, hiding the new cells from the immune system entirely.

As these technologies combine and advance, stem cell-derived beta cell therapy holds promising prospects to offer real hope for a permanent, widely available cure in the (hopefully near) future for people with diabetes.

About the author

Jessica Tian

Jessica is a PhD candidate at McGill University whose work sits at the intersection of engineering and biology. Her research focuses on developing bioprinted, microvascularized pancreatic tissues and scaling up the differentiation of iPSC-derived beta cells in suspension bioreactors. Trained as a chemical engineer, she took a slightly unconventional turn into the world of regenerative medicine and hasn’t looked back since. She’s especially excited about turning complex bioprocesses into something scalable, reproducible, and one day, clinically meaningful.